Loading
A phase 1/2 trial of Abexinostat in hodgkin lymphoma and non-hodgkin lymphoma, run by Xynomic Pharmaceuticals, Inc., active and no longer recruiting.
A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients is a phase 1/2 interventional study registered as NCT04024696 by Xynomic Pharmaceuticals, Inc., with 12 participants enrolled, started 2020-01-08 and due to reach its primary completion in 2024-12-30. Interventions recorded: Abexinostat. Conditions listed: Non Hodgkin Lymphoma. No results are recorded here; the registry entry is the source.
Shares Xynomic Pharmaceuticals, Abexinostat, Non-Hodgkin lymphoma (all types).
Shares Xynomic Pharmaceuticals, Abexinostat.
Shares Xynomic Pharmaceuticals, Abexinostat.
Shares Xynomic Pharmaceuticals, Abexinostat.